Key facts
- Notable investors include Innovestor.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Medlyse
- ·The full record, as it builds
Funding rounds
No funding rounds for Medlyse are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Medlyse
Operator of a medical diagnostics technology company intended to develop non invasive breath analysis device for early disease detection. The company uses high sensitivity sensors to measure exhaled breath biomarkers and applies AI based interpretation against a library of disease-specific VOC profiles, enabling clinicians across the patient life cycle, from newborns to the elderly, to make faster, less painful, and lab free diagnostic decisions, identify complications before they become critical, and improve patient comfort compared to invasive blood-based testing
- Sector
- Healthcare
- HQ
- Vantaa, Finland
- Founded
- 2023
- Employees
- 1
- Website
- medlyse.com/
- Ownership
- Privately Held (backing)
Medlyse doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Medlyse shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Medlyse in its N-PORT filings yet. We sweep new filings monthly.